Form 4: Arcutis Biotherapeutics Director Sells Shares Under Pre-Arranged Trading Plan

Arcutis Biotherapeutics Director Howard G. Welgus sold 9,208 shares of common stock for a weighted average price of $13.8391 per share on July 1, 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• Director Howard G. Welgus of Arcutis Biotherapeutics, Inc. (ARQT) sold shares of common stock.
• The transaction occurred on July 1, 2025.
• A total of 9,208 shares of common stock were disposed of.
• The weighted average sale price was $13.8391 per share, with individual sales ranging from $13.65 to $13.99.
• Following the sale, Welgus beneficially owns 100,206 shares of common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, which has a plan end date of May 29, 2026.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while a disposition, was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a scheduled transaction rather than a reaction to immediate negative company news. This mitigates the negative sentiment typically associated with unplanned insider selling.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled sale rather than a reaction to immediate market conditions or negative news.

Negatives

• A director sold a significant number of shares (9,208 shares), which can sometimes be perceived as a lack of confidence, even if pre-planned.

Risks

• Potential investor perception of insider selling, even if pre-planned, could lead to negative sentiment or scrutiny regarding the company's future prospects.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: May interpret the sale as a director reducing their stake, though the pre-planned nature of the Rule 10b5-1 transaction generally lessens concerns about immediate negative company sentiment.

Next Steps

• The Rule 10b5-1 trading plan under which these transactions were effected is scheduled to end on May 29, 2026.

Key Dates

Recommendation

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, insider trading, stock sale, director, Howard G. Welgus, Rule 10b5-1, common stock